This is the first in what I hope will be a series of updates on potential T1 cures and other research of note. Just remember - mice aren’t people, and most drugs fail to get out of testing.
With that out of the way:
Israeli researchers have discovered a way to get mouse immune systems to tolerate islet cell transplants without a lifetime of antirejection drugs. They use an anti-inflammatory drug called alpha-1-antitrypsin, or AAT. Even after drug administration stopped, the transplanted islets kept working and the immune system would still reject other tissue grafts.
And, of course, there was the $40 million dollar donation to the University of Minnesota.
There may be a link between diabetes and celiac disease, which could indicate that there is a dietary trigger for T1 diabetes. http://health.usnews.com/articles/health/healthday/2008/12/10/genetic-link-between-type-1-diabetes-celiac.html; http://content.nejm.org/cgi/content/full/NEJMoa0807917 for the actual New England Journal of Medicine article.
Viaject, an extremely fast-acting form of insulin, continues to analyze data from its phase III trials, according to its earnings conference call. http://seekingalpha.com/article/110142-biodel-inc-f4q08-qtr-end-10-31-08-earnings-call-transcript
Diamyd is planning to test its T1 treatment, already in phase III for “regular” T1 and pre-phase III for LADA, as a vaccine to prevent T1. http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20081209005530&newsLang=en
Novocell, a San Diego-based stem cell engineering company, will collaborate with Japanese researcher Shinya Yamanaka of Kyoto University on stem-cell based treatments for T1 diabetes, using Yamanaka’s method of causing adult cells to return to pluripotent form. (Pluripotent cells are capable of becoming any type of cell.) http://www.sdbj.com/article.asp?aID=0674958.2673435.1718600.38076502.3910533.846&aID2=132191.
That’s all for now. Have a great night, and enjoy your weekends!